 The purpose of this study is to evaluate the pharmacokinetic interactions between simeprevir and ledipasvir in a treatment regimen consisting of simeprevir SMV, sofosbuvir SOF, and ledipasvir LDV in treatment-naive participants with chronic hepatitis C virus HCV genotype 1 infection. 